French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Wednesday that the US Food and Drug Administration has granted orphan drug designation to SAR446523 for the potential treatment of relapsed or refractory multiple myeloma.
SAR446523 is an IgG1-based monoclonal antibody designed to enhance Antibody-Dependent Cellular Cytotoxicity. It targets GPRC5D, a receptor highly expressed in multiple myeloma cells with limited presence in healthy tissues.
The orphan designation applies to therapies intended for rare diseases affecting fewer than 200,000 patients in the United States.
Sanofi highlighted the designation as a key milestone in its multiple myeloma research and development efforts.
According to the company, SAR446523 builds on its established expertise in the therapeutic area, which includes a previously approved immunotherapy.
The investigational treatment remains under clinical evaluation, and its safety and efficacy have not yet been assessed by any regulatory authority.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval